Enterprise Innovation

Weill Cornell Medicine Enterprise Innovation engages and collaborates with Weill Cornell Medicine faculty and trainees while fostering alliances with leaders in the biomedical industry and business and investment community. Our focus is to translate the application of emerging science and new technologies into world-class medical breakthroughs.

Integrating Weill Cornell Medicine’s different teams and resources under a single, united organization, Enterprise Innovation encompasses the entire spectrum of an effective innovation ecosystem. We offer unique opportunities for faculty and trainees to transform their research into medical advances through collaborations including access to the Sanders Tri-Institutional Therapeutics Discovery Institute.

News

Gene Therapy Shows Promise for Life-Threatening Inherited Heart Disease

June 17, 2026

A new gene therapy appears to be safe in patients diagnosed with Friedreich ataxia cardiomyopathy, a progressive and fatal inherited cardiac disease, according to a phase 1...
Innovators Pitch Cell Therapies and AI Tools at Biomedical Innovation Challenge

June 10, 2026

The eighth cohort of the Biomedical Innovation Challenge showcased its innovations and development plans during a lightning round of pitches and judges’ questions on June 4 in the...
A Breakthrough Single-Cell Method for Mapping DNA-Protein Interactions

June 4, 2026

A new technology allows scientists to map, in single cells, the DNA binding sites of transcription factors and other regulatory proteins that control gene activity, according to a...